Ignite Creation Date:
2025-12-24 @ 12:13 PM
Ignite Modification Date:
2026-03-04 @ 6:05 PM
Study NCT ID:
NCT03066661
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2019-04-26
First Post:
2017-02-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
Sponsor:
Hoffmann-La Roche
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
Entrectinib (RXDX-101) - EAP
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None